December 21, 2010 – A once-daily, three-in-one combination blood pressure treatment has been approved in Germany. Sevikar HCT, from Daiichi Sankyo Europe, combines olmesartan medoxomil, amlodipine, and hydrochlorothiazide (HCT) in one pill to help control hypertension.
The pill is indicated as substitution therapy in adults whose blood pressure is adequately controlled on the combination of the three drugs, taken as a dual-component and a single-component formulation.
Evidence shows that up to two-thirds of hypertensive patients require multiple medications, and many need three or more to reach the accepted blood pressure goal of 140/90 mmHg. The fixed-dose combination therapy simplifies treatment, provides patients with a more convenient option and decreases overall pill burden. Giving drugs as a single-pill fixed dose combination significantly improves compliance, and favors blood pressure control compared with the same drugs given separately as two or more pills.
Hypertension is one of the most prevalent conditions in Europe, affecting approximately one in three adults and nearly one billion people worldwide.
For more information: www.daiichisankyo.com
November 19, 2025 
